Successful treatment with a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) for a patient with relapsed mantle cell lymphoma who developed a human anti-chimeric antibody (Q74447937)

From Wikidata

Jump to navigation Jump to search

scientific article published on 01 July 2001

Language	Label	Description	Also known as
English	Successful treatment with a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) for a patient with relapsed mantle cell lymphoma who developed a human anti-chimeric antibody	scientific article published on 01 July 2001

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11530808%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

Successful treatment with a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) for a patient with relapsed mantle cell lymphoma who developed a human anti-chimeric antibody (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11530808%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

mantle cell lymphoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

monoclonal antibody

1 reference

based on heuristic

inferred from title

author name string

T Maeda

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11530808%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

Y Yamada

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11530808%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

M Tawara

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11530808%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

R Yamasaki

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11530808%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

Y Yakata

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11530808%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

C Tsutsumi

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11530808%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

Y Onimaru

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11530808%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

S Kamihira

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11530808%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

M Tomonaga

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11530808%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

publication date

1 July 2001

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11530808%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

International Journal of Hematology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11530808%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

74

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11530808%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11530808%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

70-75

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11530808%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/11530808

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/11530808

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of the mouse monoclonal antibody 17-1A in cancer patients receiving various treatment schedules

1 reference

https://pubmed.ncbi.nlm.nih.gov/11530808

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Malignant lymphoma, intermediate lymphocytic type: a clinicopathologic study of 42 cases

1 reference

https://pubmed.ncbi.nlm.nih.gov/11530808

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data

1 reference

https://pubmed.ncbi.nlm.nih.gov/11530808

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11530808

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mantle-zone lymphoma: a follicular variant of intermediate lymphocytic lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/11530808

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytological and functional criteria for the classification of malignant lymphomata

1 reference

https://pubmed.ncbi.nlm.nih.gov/11530808

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Initial experience evaluating 90yttrium-radiolabeled anti-carcinoembryonic antigen chimeric T84.66 in a phase I radioimmunotherapy trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/11530808

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Growth inhibition of CD20-positive B lymphoma cell lines by IDEC-C2B8 anti-CD20 monoclonal antibody

1 reference

https://pubmed.ncbi.nlm.nih.gov/11530808

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/11530808

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/11530808

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mantle cell lymphoma: a retrospective study of 121 cases

1 reference

https://pubmed.ncbi.nlm.nih.gov/11530808

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/11530808

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/11530808

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project

1 reference

https://pubmed.ncbi.nlm.nih.gov/11530808

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/11530808

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/11530808

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project

1 reference

https://pubmed.ncbi.nlm.nih.gov/11530808

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/11530808

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11530808

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11530808

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q74447937&oldid=2220314706"